DCLK1 Antibody

What is DCLK1 and why is it important in research?

DCLK1 (doublecortin like kinase 1) is a serine/threonine protein kinase with a molecular weight of approximately 82.2 kilodaltons. It exists in multiple isoforms, with the two major variants being the long isoform (DCLK1-L) and short isoform (DCLK1-S). DCLK1 has emerged as a significant marker in cancer stem cell (CSC) research and has been implicated in various malignancies including gastric cancer, colorectal cancer, and esophageal squamous cell carcinoma. Its importance lies in its potential role as a prognostic marker and therapeutic target, particularly in gastrointestinal cancers .

What are the major isoforms of DCLK1 and how do they differ structurally?

DCLK1 has two principal isoforms: DCLK1-L (long) and DCLK1-S (short). The long isoform contains N-terminal doublecortin domains which the short isoform lacks. Instead, DCLK1-S has a unique N-terminal six amino acid sequence that distinguishes it from the long isoform. Both isoforms share common C-terminal regions. This structural difference is crucial for researchers designing experiments, as many commercial antibodies target either the C-terminal region (detecting both isoforms) or specifically the N-terminal doublecortin domains (detecting only DCLK1-L) .

What types of DCLK1 antibodies are commercially available?

Commercial DCLK1 antibodies fall into several categories based on their epitope targets:

• Antibodies targeting the C-terminal end, which recognize both long and short isoforms

• Antibodies targeting the N-terminal doublecortin domains, which recognize only the DCLK1-L isoform

• Recently developed monoclonal antibodies specific to the unique N-terminal sequence of DCLK1-S

These antibodies are available in various formats including unconjugated forms and those conjugated with tags such as biotin, FITC, HRP, and Alexa fluorophores. They are produced in different host species and are applicable to various techniques including Western blot, immunohistochemistry, immunofluorescence, ELISA, and flow cytometry .

How should I select the appropriate DCLK1 antibody for my specific research question?

Selection of the appropriate DCLK1 antibody depends on several factors:

• Target isoform specificity: Determine whether you need to detect both DCLK1 isoforms or specifically DCLK1-L or DCLK1-S. If isoform discrimination is critical, select antibodies that target unique domains.

• Experimental application: Consider the intended application (Western blot, IHC, IF, flow cytometry). Not all antibodies perform equally across different applications. Review validation data for your specific application.

• Species reactivity: Ensure the antibody recognizes DCLK1 in your experimental species. Many antibodies detect human, mouse, and rat orthologs, but cross-reactivity varies.

• Epitope location: Consider whether the epitope location might be affected by post-translational modifications or protein-protein interactions in your experimental context.

• Validation evidence: Prioritize antibodies with extensive validation data in contexts similar to your research question .

What are the optimal conditions for using DCLK1 antibodies in immunohistochemistry?

For optimal immunohistochemical detection of DCLK1:

• Fixation: Standard formalin fixation and paraffin embedding typically work well, but optimization may be required for specific antibodies.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is commonly effective, but some antibodies may require EDTA buffer (pH 9.0).

• Antibody dilution: Start with the manufacturer's recommended dilution and optimize as needed. For many DCLK1 antibodies, dilutions between 1:100 and 1:500 are appropriate.

• Incubation conditions: Overnight incubation at 4°C often yields the best signal-to-noise ratio, though shorter incubations at room temperature may be sufficient.

• Detection system: Use detection systems appropriate for the host species of the primary antibody. HRP-polymer systems often provide excellent sensitivity.

• Controls: Include positive controls (tissues known to express DCLK1) and negative controls (primary antibody omission or pre-adsorption with immunizing peptide) .

How can I validate the specificity of a DCLK1 antibody in my experimental system?

Comprehensive validation should include:

• Peptide competition assay: Pre-adsorb the antibody with the immunizing peptide to demonstrate binding specificity. This approach was used successfully to validate the 2H3D5 monoclonal antibody against DCLK1-S.

• Isotype control: Replace the primary antibody with the corresponding IgG isotype to identify non-specific binding.

• Known positive and negative tissues: Test the antibody on tissues with documented DCLK1 expression patterns. For example, specific DCLK1-S antibodies should show differential staining in gastric cancer versus normal gastric tissues.

• Molecular weight confirmation: In Western blotting, confirm that the detected band corresponds to the expected molecular weight (approximately 82.2 kDa for full-length DCLK1).

• Genetic manipulation: If possible, test antibody reactivity in systems with DCLK1 knockdown or overexpression to confirm specificity .

How can I differentiate between DCLK1-S and DCLK1-L expression in tumor tissues?

Differentiating between DCLK1 isoforms requires strategic antibody selection and experimental design:

• Isoform-specific antibodies: Use antibodies that specifically target either DCLK1-S (targeting the unique N-terminal sequence) or DCLK1-L (targeting the doublecortin domains absent in DCLK1-S).

• Comparative immunostaining: Perform parallel staining with both isoform-specific antibodies and a pan-DCLK1 antibody (targeting the common C-terminal region) to assess relative expression levels.

• Western blot analysis: The different molecular weights of the isoforms allow for differentiation by Western blotting.

• RT-PCR with isoform-specific primers: Complement protein detection with mRNA analysis using primers specific to each isoform.

• Subcellular localization: Assess subcellular distribution, as research indicates different localizations may occur between isoforms, with DCLK1-S showing both membrane and cytoplasmic expression in gastric cancer tissues .

What methods can be used to quantify DCLK1 expression in tissue samples?

Several quantification approaches are available:

• H-score method: Calculate an H-score by multiplying the percentage of positive cells (0-100%) by staining intensity (0-3), resulting in a score from 0-300. This approach was used in studies of DCLK1-S expression in gastric cancer tissues.

• Digital image analysis: Use software to quantify staining intensity and percentage of positive cells more objectively.

• Flow cytometry quantification: For cell suspensions or disaggregated tissues, flow cytometry provides precise quantification of DCLK1 expression levels, as demonstrated in studies with gastric cancer cell lines like MKN-45 and AGS.

• Western blot densitometry: Quantify band intensity relative to loading controls for semiquantitative assessment of protein levels.

• qRT-PCR: Complement protein quantification with mRNA expression analysis using appropriate reference genes .

How should DCLK1 antibody results be interpreted in the context of cancer stem cell research?

Interpretation requires careful consideration of several factors:

• Isoform-specific expression patterns: The DCLK1-L and DCLK1-S isoforms may have different functional roles and prognostic implications. For example, high DCLK1-S expression correlates with favorable survival in gastric cancer but worse survival in colorectal cancer.

• Cell type specificity: Consider which cells express DCLK1 within the tumor microenvironment. Cancer stem cells may show different expression patterns than bulk tumor cells.

• Subcellular localization: Membrane, cytoplasmic, and nuclear localization may have different functional implications. In gastric cancer, DCLK1-S shows prominent membrane and cytoplasmic expression.

• Correlation with clinicopathological features: Analyze DCLK1 expression in relation to tumor stage, grade, and patient outcomes. Research indicates a negative correlation between DCLK1-S expression and gastric cancer invasiveness.

• Integration with other CSC markers: Evaluate DCLK1 expression in conjunction with other established cancer stem cell markers for comprehensive characterization .

Why might I observe inconsistent results with different DCLK1 antibodies?

Inconsistencies can arise from several factors:

• Epitope accessibility: Different antibodies target different epitopes that may be differentially accessible depending on fixation, tissue processing, or protein conformation.

• Isoform specificity: Some antibodies detect both DCLK1-L and DCLK1-S, while others are isoform-specific. This can lead to apparently conflicting results if isoforms have different expression patterns or functions.

• Antibody quality and validation: Commercial antibodies vary in specificity and sensitivity. Thoroughly validated antibodies, such as the 2H3D5 monoclonal antibody against DCLK1-S, generally provide more reliable results.

• Technical variables: Differences in antigen retrieval methods, detection systems, and staining protocols can affect results.

• Biological variation: DCLK1 expression varies by tissue type, cancer subtype, and disease stage. For instance, DCLK1-S expression decreases with higher histological grade and pT stage in gastric cancer .

What are common pitfalls in DCLK1 antibody-based experiments and how can they be avoided?

Common pitfalls include:

• Inadequate controls: Always include positive and negative controls. For DCLK1-S specificity, researchers successfully used primary antibody pre-adsorption with immunizing peptide and IgG replacement as negative controls.

• Overgeneralization of findings: Results from one cancer type may not translate to others. For example, DCLK1-S expression has opposite prognostic implications in gastric cancer versus esophageal squamous cell carcinoma.

• Insufficient isoform discrimination: Using antibodies that detect both isoforms without acknowledging this limitation can lead to misinterpretation, especially if the isoforms have opposing functions.

• Non-specific binding: High background can obscure true signals. Optimize blocking conditions and antibody dilutions, and consider using monoclonal antibodies which typically have higher specificity.

• Misinterpretation of subcellular localization: Be precise about localization patterns. DCLK1-S shows both membrane and cytoplasmic localization in gastric cancer cells .

How does DCLK1 expression correlate with clinicopathological features in different cancer types?

DCLK1 expression shows cancer type-specific correlations:

These contrasting findings highlight the importance of cancer-specific and isoform-specific analysis when evaluating DCLK1 as a biomarker .

What is the significance of membrane versus cytoplasmic DCLK1 localization in tumor tissues?

Subcellular localization provides important functional insights:

• Membrane localization: In gastric cancer, DCLK1-S shows prominent membrane expression, which may relate to its role in maintaining tight junctions and epithelial barrier function. Cells lacking DCLK1 are reportedly unable to restore impaired tight junctions.

• Cytoplasmic localization: Cytoplasmic DCLK1-S expression in colorectal cancer associates with cancer aggressiveness and worse disease-specific survival, suggesting different functional roles in different cellular compartments.

• Differential expression patterns: DCLK1-S expression is considerably higher in both membrane and cytoplasm of cancer cells in gastric cancer tissues compared to adjacent normal tissues.

• Functional implications: The localization pattern may reflect DCLK1's involvement in different cellular processes, including DNA damage response (DDR) and maintenance of tight junctions, potentially explaining why high DCLK1-S expression serves as a favorable clinical marker in gastric cancer patients .

What are the emerging applications of DCLK1 isoform-specific antibodies in cancer research?

Emerging applications include:

• Prognostic stratification: Isoform-specific antibodies allow for more precise patient stratification. For example, high DCLK1-S expression correlates with favorable prognosis in gastric cancer but poor prognosis in colorectal cancer.

• Therapeutic target validation: As potential therapeutic targets emerge, isoform-specific antibodies will be crucial for validating target expression in patient samples and monitoring treatment response.

• Cancer stem cell identification: More precise characterization of cancer stem cell populations based on DCLK1 isoform expression patterns.

• Mechanistic studies: Investigation of isoform-specific functions in cancer progression, such as DCLK1-S's role in DNA damage response and tight junction stability.

• Companion diagnostics: Development of diagnostic assays to guide treatment decisions for therapies targeting specific DCLK1 isoforms .

How can I resolve contradictory findings regarding DCLK1 expression and prognosis across different studies?

To reconcile contradictory findings:

• Isoform specification: Determine which DCLK1 isoform was detected in each study. Many earlier studies used antibodies that could not distinguish between DCLK1-L and DCLK1-S.

• Cancer type consideration: DCLK1 appears to have tissue-specific and cancer-specific roles. For example, high DCLK1-S expression is favorable in gastric cancer but unfavorable in colorectal cancer.

• Methodological differences: Evaluate differences in antibodies used, scoring criteria, cutoff values for expression classification, and follow-up duration.

• Cellular context: Consider which cell types were examined and whether the focus was on bulk tumor or specific tumor subpopulations.

• Integrated analysis: When possible, conduct meta-analyses or integrate findings across multiple studies to identify consistent patterns despite methodological variations .

What technical advantages do monoclonal antibodies offer over polyclonal antibodies for DCLK1 research?

Monoclonal antibodies provide several advantages:

• Epitope specificity: They recognize a single epitope, resulting in higher specificity. This is particularly valuable for distinguishing between DCLK1 isoforms, as demonstrated by the 2H3D5 monoclonal antibody against DCLK1-S.

• Batch consistency: Unlike polyclonal antibodies, monoclonals show minimal batch-to-batch variation, enhancing experimental reproducibility.

• Background reduction: Typically produce cleaner results with less non-specific binding. The 2H3D5 clone showed specific immunostaining patterns with gastric cancer tissue specimens with minimal non-specific reactivity.

• Superior performance at low concentrations: Generated monoclonal clones recognized mouse DCLK1-S peptides well in ELISA even at low antibody concentrations, displaying high binding affinity.

• Validation precision: Easier to validate definitively due to their single-epitope binding characteristic .

What cellular functions of DCLK1 might explain its different prognostic implications across cancer types?

Several functional roles may explain tissue-specific effects:

• Tight junction maintenance: DCLK1 appears essential for restoring impaired tight junctions. This function may be particularly important in gastric cancer, where high DCLK1-S expression correlates with better outcomes.

• DNA damage response (DDR): DCLK1-S plays a role in generating functional DDR, which may have different implications depending on the genomic stability of different cancer types.

• Cell invasion regulation: Lower DCLK1-S expression correlates with higher invasive potential in gastric cancer cell lines, with MKN-45 cells (higher invasive potential) expressing lower surface DCLK1-S than less invasive AGS cells.

• Cancer stem cell maintenance: DCLK1's role as a cancer stem cell marker may have different implications depending on the biology of stem-like cells in different tissues.

• Organ-specific microenvironment interactions: The tumor microenvironment varies considerably between organs, potentially altering the functional consequences of DCLK1 expression .

What are the optimal conditions for immunohistochemical detection of DCLK1-S in tissue microarrays?

For optimal DCLK1-S detection in TMAs:

• Antibody selection: Use isoform-specific antibodies like the 2H3D5 monoclonal antibody that specifically targets the unique N-terminal six amino acids sequence of DCLK1-S.

• Tissue processing: Standard formalin fixation and paraffin embedding protocols are typically effective.

• Antigen retrieval: Optimize based on specific antibody requirements; heat-induced epitope retrieval is generally effective.

• Blocking: Thorough blocking of endogenous peroxidase activity and non-specific binding sites is crucial for clean results.

• Scoring methodology: Consider using an H-score system that accounts for both staining intensity and percentage of positive cells, as used in clinical studies of DCLK1-S in gastric cancer.

• Validation controls: Include peptide competition controls and isotype controls to verify specificity, especially when using newly developed antibodies .

What methodological approaches can be used to study DCLK1 isoform expression at the single-cell level?

Single-cell analysis of DCLK1 can be accomplished through:

• Flow cytometry: Allows quantitative assessment of DCLK1 isoform expression in cell populations. Studies have successfully used flow cytometry to compare DCLK1-S levels between gastric cancer cell lines with different invasive potentials.

• Immunofluorescence microscopy: Enables visualization of subcellular localization patterns and co-expression with other markers.

• Single-cell RNA sequencing: Provides transcriptomic profiles that can distinguish between DCLK1 isoform expression at the mRNA level.

• Mass cytometry (CyTOF): Allows simultaneous detection of multiple proteins, including DCLK1 isoforms, without fluorescence overlap limitations.

• In situ hybridization: Techniques like RNAscope can detect specific DCLK1 isoform transcripts in tissue sections while preserving spatial context .

How should DCLK1 antibody validation be documented for publication?

Comprehensive validation documentation should include:

• Specificity tests: Document peptide competition assays, isotype controls, and testing in known positive and negative tissues. The 2H3D5 anti-DCLK1-S mAb was validated by showing no positive staining in normal testis tissue, cancerous ovarian and skin tissues when primary antibody was pre-adsorbed with immunizing peptide or replaced with mouse IgG.

• Western blot analysis: Show full blot images with molecular weight markers to confirm the detected protein matches the expected size of the DCLK1 isoform.

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related proteins, particularly other doublecortin family members.

• Reproducibility evidence: Demonstrate consistent results across multiple experiments and biological replicates.

• Positive controls: Include tissues or cell lines with well-documented DCLK1 expression patterns.

• Application-specific validation: Provide validation data specific to each experimental application (WB, IHC, IF, etc.) .

How might DCLK1 isoform-specific antibodies contribute to targeted cancer therapies?

DCLK1 isoform-specific antibodies could advance cancer therapeutics through:

• Patient stratification: Identifying patients most likely to benefit from DCLK1-targeted therapies based on isoform expression patterns. For instance, gastric cancer patients with low DCLK1-S expression might be candidates for specific interventions.

• Target validation: Confirming the expression and accessibility of specific DCLK1 isoforms in patient samples before treatment.

• Antibody-drug conjugates (ADCs): Developing therapeutic antibodies against DCLK1 isoforms conjugated to cytotoxic payloads for targeted delivery to cancer cells.

• Functional blocking: Creating antibodies that specifically inhibit the functional domains of DCLK1 isoforms.

• Monitoring treatment response: Using isoform-specific antibodies to track changes in DCLK1 expression during treatment .

What is known about the differential expression of DCLK1 isoforms across normal and cancerous tissues?

Expression patterns show important tissue-specific differences:

• Gastric tissues: DCLK1-S expression is significantly higher in gastric cancer tissues compared to adjacent normal tissues, with membrane and cytoplasmic localization in cancer cells.

• Expression gradients: In gastric cancer, DCLK1-S expression negatively correlates with cancer progression, with lower expression in higher histological grades and more advanced pT stages.

• Cell line models: Different cancer cell lines show varying DCLK1-S expression levels that correlate with their invasive potential. For example, MKN-45 cells with higher invasive potential express lower surface DCLK1-S levels than less invasive AGS cells.

• Colorectal tissue differences: In contrast to gastric cancer, high cytoplasmic DCLK1-S expression in colorectal cancer associates with cancer aggressiveness and worse disease-specific survival.

• Organ-specific patterns: The contradictory clinical impacts of DCLK1-S expression between different cancers suggests organ-specific functions .

Table 1: DCLK1 Antibody Applications and Specifications

Table 2: DCLK1 Isoform Comparison